Tissue factor upregulation drives a thrombosis-inflammation circuit in relation to cardiovascular complications

Cell Biochemistry and Function

Volumn 24, Issue 2, 2006, Pages 173-192

  Chu, Arthur J ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHANTOU UNIVERSITY   (China)

Author keywords

Anticoagulation; Cardiovascular disorder; Hypercoagulability; Inflammation; Sepsis; Thrombosis; Tissue factor

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 4 (4 AMIDINOPHENOXY)BUTYRYLASPARTYLVALINE; ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN III; ARGATROBAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A INHIBITOR; CD18 ANTIGEN; CELL ADHESION MOLECULE; CYTOKINE; ENOXAPARIN; ENZYME PRECURSOR; FIBRIN; HEPARIN DERIVATIVE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 8; LOW MOLECULAR WEIGHT HEPARIN; MONOCLONAL ANTIBODY; PROSTACYCLIN; PROTHROMBIN A; THROMBOPLASTIN; THROMBOPLASTIN ANTIBODY; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CELL COMMUNICATION; CELL TYPE; CLINICAL PATHWAY; FEEDBACK SYSTEM; HEART PROTECTION; HUMAN; HYPERCOAGULABILITY; IMMUNOPATHOGENESIS; INFLAMMATION; LEUKOCYTE ACTIVATION; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; THROMBOCYTE ACTIVATION; THROMBOSIS; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; FACTOR VII; HUMANS; INFLAMMATION; SIGNAL TRANSDUCTION; THROMBOPLASTIN; THROMBOSIS; UP-REGULATION;

EID: 33645331296     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1200     Document Type: Review

References (282)

1. Hunt TK, Hopf H, Hussain Z. Physiology of wound healing. Adv. Skin Wound Care 2000; 13: 6-11.
2. Browder T, Folkman J, Pine-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000; 275: 1521-1524.
3. Ruf W. Molecular regulation of blood clotting in tumor biology. Haemostasis 2001; 31(Suppl. 1): 5-7.
4. Opal SM. Interactions between coagulation and inflammation. Scand J Infect Dis 2003; 35: 545-554.
5. Broze GJ, Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46: 103-112.
6. Astic ME. Septic shock. Lancet 1998; 352: 1501-1505.
7. Hardaway RM, Williams CH, Vasquez Y. Disseminated intravascular coagulation in sepsis. Semin Thromb Hemost 2001; 27: 577-583.
8. Lorenzet R, Napoleone E, Celi A, Pellegrini G, Di Santo A. Cell-cell interaction and tissue factor expression. Blood Coagul Fibrinolysis 1998; 9(Suppl.): S49-S59.
9. Pokhilko AV. Intrinsic coagulation pathway: an activation threshold. Thromb Res 2000; 99: 285-293.
10. Thomas RH. Hypercoagulability syndromes. Arch Intern Med 2001; 161: 2433-2439.
11. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diab Complications 2001; 15: 44-54.
12. Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Haemost 1999; 25: 137-145.
13. Norris LA, Bonnar J. Haemostatic changes and the oral contraceptive pills. Baillieres Clin Obstet Gynaecol 1997; 11: 545-564.
14. Chu AJ. Biochemical strategies to anticoagulation: a comparative overview. Curr Vasc Pharmacol 2004; 4: 199-228.
15. Rao LVM, Rapaport S. Activation of factor Vu bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA 1988; 85: 6687-6691.
16. Mackman N, Brand K, Edgington TS. Lipopolysaccharide-mediated transcriptional activation of the human tissue factor gene in THP-1 monocytic cells requires both activator protein 1 and nuclear factor kappa B binding sites. J Exp Med 1991; 174: 1517-1526.
17. Chu AJ, Raphael UO, Prasad JK, Beydoun S, Ramos N. II. Compound 48/80 suppresses monocytic tissue factor-initiated extrinsic blood coagulation induced by bacetrial endotoxin. J Surg Res 1999; 87: 252-257.
18. Scarpati EM, Sadler JE. Regulation of endothelial cell coagulant properties: modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor. J Biol Chem 1989; 264: 20705-20713.
19. Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica 2000; 85: 967-972.
20. Tanaka M, Kishi T. Induction of tissue factor by interleukin-2 in acute myelogenous leukemia (AML) cells. Growth Factors 1990; 4: 1-8.
21. Christian M, Marangos P, Mak I, et al. Interferon-gamma modulates prolactin and tissue factor expression in differentiating human endometrial stromal cells. Endocrinology 2001; 142: 3142-3151.
22. Herkert O, Diebold I, Brandes RP, Hess J, Busse R, Gorlach A. NADPH oxidase mediates tissue factor-dependent surface procoagulant activity by thrombin in human vascular smooth muscle cells. Circulation 2002; 105: 2030-2036.
23. Syrovets T, Jendrach M, Rohwedder A, Schule A, Simmet T. Plasmin-induced expression of cytokines and tissue factor in human monocytes involves AP-1 and IKKbeta-mediated NF-kappaB activation. Blood 2001; 97: 3941-3950.
24. Mechtcheriakova D, Schabbauer G, Lucerna M, et al. Specificity, diversity, and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J 2001; 15: 230-242.
25. Xuereb JM, Sie P, Boneu B, Constans J. Up-regulation of tissue factor expression by platelet-derived growth factor in human vascular smooth muscle cells in culture-role of mitogen-activated protein kinase and effects of intracellular cyclic AMP. Thromb Haemost 1997; 78: 1520-1526.
26. Schecter AD, Rollins BJ, Zhang YJ, et al. Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells. J Biol Chem 1997; 272: 28568-28573.
27. Ernofsson M, Siegbahn A. Platelet-derived growth factor-BB and monocyte chemotactic protein-1 induce human peripheral blood monocytes to express tissue factor. Thromb Res 1996; 83: 307-320.
28. Bea F, Puolakkainen MH, McMillen T, et al. Chlamydia pneumoniae induces tissue factor expression in mouse macrophages via activation of Egr-1 and the MEK-ERK1/2 pathway. Circ Res 2003; 92: 394-401.
29. Lee WH, Kim SH, Jeong EM, et al. A novel chemokine, Leukotactin-1, induces chemotaxis, pro-atherogenic cytokines, and tissue factor expression in atherosclerosis. Atherosclerosis 2002; 161: 255-260.
30. Celi A, Pellegrini G, Lorenzet R, et al. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci USA 1994; 91: 8767-8771.
31. Brand K, Banka CL, Mackman N, Terkeltaub RA, Fan ST, Curtiss LK. Oxidized LDL enhances lipopolysaccharide-induced tissue factor expression in human adherent monocytes. Arterioscler Thromb 1994; 14: 790-797.
32. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein (a) to fibrin: a potential biochemical link between thrombosis, atherogeneis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992; 89: 10193-10197.
33. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arteriosclerosis Thromb 1993; 13: 1327-1333.
34. Xie S, O'Regan DJ, Kakkar W, Scully MF. 15 deoxy delta12,14 PGJ2 induces procoagulant activity in cultured human endothelial cells. Thromb Haemost 2002; 87: 523-529.
35. Maderna P, Godson C, Hannify G, Murphy M, Brady HR. Influence of lipoxin A4 and other lipoxygenase-derived eicosanoid on tissue factor expression. Am J Physiol Cell Physiol 279: C945-C953.
36. Muller DN, Mervaala EM, Schmidt F, et al. Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension 2000; 36: 282-290.
37. Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y. C5a induces tissue factor activity on endothelial cells. Thromb Res 2000; 77: 394-398.
38. Siddiqui FA, Amirkhosravi A, Amaya M, et al. Hemoglobin enhances tissue factor expression on human malignant cells. Blood Coagul Fibrinolysis 2001; 12: 171-177.
39. De Somer F, Van Belleghem Y, Case F, et al. Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2002; 123: 951-958.
40. Bertina RM, van den Besselaar AMHP, Bom VJJ. Tissue thromboplastin and the initiation of coagulation. In Coagulation and Lipids, Zweal RFA (ed.). CRC Press: Boca Raton, 1989; 131-158.
41. Herbert JM, Corseaux D, Laie A, Bernat A. Hypoxia primes endotoxin-induced tissue factor expression in human monocytes and endothelial cells by a PAF-dependent mechanism. J Cell Physiol 1996; 169: 290-299.
42. Williams MA, White SA, Miller JJ, et al. Granulocyte-macrophage colony-stimulating factor induces activation and restores respiratory burst activity in monocytes from septic patients. J Infect Dis 1998; 177: 107-115.
43. Eilertsen KE, Olsen JO, Osterud B. Ex-vivo regulation of endotoxin-induced tissue factor in whole blood by eicosanoids. Blood Coagul Fibrinolysis 2003; 14: 41-48.
44. Marx N, Neumann FJ, Zohlnhofer D, et al. Enhancement of monocyte procoagulant activity by adhesion on vascular smooth muscle cells and intercellular adhesion molecule-1-transfected Chinese hamster ovary cells. Circulation 1998; 98: 906-911.
45. Collins PW, Noble KE, Reittie JR, Hoffbrand AV, Pasi KJ, Yong KL. Induction of tissue factor expression in human monocyte/endothelium cocultures. Br J Haematol 1995; 91: 963-970.
46. Lo SK, Cheung A, Zheng Q, Silverstein RL. Induction of tissue factor on monocytes by adhesion to endothelial cells. J Immunol 1995; 154: 4768-4777.
47. Schmid E, Muller TH, Budzinski RM, Pfizenmaier K, Binder K. Lymphocyte adhesion to human endothelial cells induces tissue factor expression via a juxtacrine pathway. Thromb Haemost 1995; 73: 421-428.
48. Ternisien C, Ollivier V, Khechai F, Ramani M, Hakim J, de Prost D. Protein tyrosine kinase activation is required for LPS and PMA induction of tissue factor mRNA in human blood monocytes. Thromb Haemost 1995; 73: 413-420.
49. Guha M, O'Connell MA, Pawlinski R, et al. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood 2001; 98: 1429-1439.
50. McGilvray ID, Tsai V, Marshall JC, Dackiw AP, Rotstein OD. Monocyte adhesion and transmigration induce tissue factor expression: role of the mitogen-activated protein kinases. Shock 2002; 18: 51-57.
51. Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood 1997; 89: 2429-2442.
52. Chu AJ, Prasad JK. Antagonism by IL-4 and IL-10 of endotoxin-induced tissue factor activation in monocytic THP-1 cells: activating role of CD14 ligation. J Surg Res 1998; 80: 80-87.
53. Xuereb JM, Sie P, Boneu B, Constans J. Inhibition of tissue factor synthesis by disruption of ERK kinases and PKC signaling pathways in human vascular SMCs. Thromb Haemost 2000; 84: 129-136.
54. Ternisien C, Ramani M, Ollivier V, et al. Endotoxin-induced tissue factor in human monocytes is dependent upon protein kinase C activation. Thromb Haemost 1993; 70: 800-806.
55. Cui MZ, Penn MS, Chisolm GM. Native and oxidized low density lipoprotein induction of tissue factor gene expression in smooth muscle cells is mediated by both Egr-1 and Sp1. J Biol Chem 1999; 274: 32795-32802.
56. Engelmann B, Zieseniss S, Brand K, et al. Tissue factor expression of human monocytes is suppressed by lysophosphatidyicholine. Arterioscler Thromb Vascu Biol 1999; 1947-53.
57. Leclerc NE, Haan-Archipoff G, Lenoble M, Beretz A. Inhibitors of phosphodiesterase (pentoxifylline, trequinsin) inhibit apical and subcellular matrix expression of tissue factor in cultured human endothelial cells. J Cardiovasc Pharmacol 1995; S2: S88-S91.
58. Crutchley DJ, Conanan LB, Que BG. Effects of prostacyclin analogs on the synthesis of tissue factor, tumor necrosis factor-alpha and interleukin-1 beta in human monocytic THP-1 cells. J Pharmacol Exp Ther 1994; 271: 446-451.
59. Sugano T, Tsuji H, Masuda H, et al. Adrenomedullin inhibits angiotensin II-induced epression of tissue factor and plasminogen activator inhibitor-1 in cultured rat aortic endothelial cells. Arterioscler Thromb Vasc Biol 2001; 21: 1078-1083.
60. Gabazza EC, Hayashi T, Ido M, Adachi Y, Suzuki K. Adenosine inhibits thrombin-induced expression of tissue factor on endothelial cells by a nitric oxide-mediated mechanism. Clin Sci (Lond) 2002; 102: 167-175.
61. Deguchi H, Takeya H, Urano H, Gabazza EC, Zhou H, Suzuki K. Adenosine regulates tissue factor expression on endothelial cells. Thromb Res 1998; 91: 57-64.
62. Chu AJ, Wang ZG, Walton MA, Seto A. Involvement of MAPK activation in bacterial endotoxin-inducible tissue factor upregulation in human monocytic THP-1 cells. J Surg Res 2001; 101: 85-90.
63. Bierhaus A, Zhang Y, Quehenberger P, et al. The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-kappa B. Thromb Haemost 1997; 77: 772-782.
64. Pendurthi UR, Williams JT, Rao LV. Inhibition of tissue factor gene activation in cultured endothelial cells by curcumin: suppression of activation of transcription factors Egr-1, AP-1, and NF-kappa B. Arterioscler Thromb Vasc Biol 1997; 17: 3406-3413.
65. Lindmark E, Siegbahn A. Tissue factor regulation and cytokine expression in monocyte-endothelial cell co-cultures: effects of a statin, an ACE-inhibitor and a low-molecular-weight heparin. Thromb Res 2002; 108: 77-84.
66. Bea F, Blessing E, Shelley MI, Shultz JM, Rosenfeld ME. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. Atherosclerosis 2003; 167: 187-194.
67. Nguyen P, Broussas M, Hexard N, Cornillet P, Potron G. Modulator of leukocytic functions. J Mal Vasc 1998; 23: 119-124.
68. Osnes LT, Foss KB, Joo GB, et al. Acetylsalicylic acid and sodium salicylate inhibit LPS-induced NF-kappa B/c-Rel nuclear translocation, and synthesis of tissue factor (TF) and tumor necrosis factor alfa (TNF-alpha) in human monocytes. Thromb Haemost 1996; 76: 970-976.
69. Oeth P, Mackman N. Salicylates inhibit lipopolysaccharide-induced transcriptional activation of the tissue factor gene in human monocytic cells. Blood 1995; 86: 4144-4152.
70. Barstad RM, Hamers MJ, Stephens RW, Sakariassen KS. Retinoic acid reduces induction of monocyte tissue factor and tissue factor/factor VIIa-dependent arterial thrombus formation. Blood 1995; 86: 212-218.
71. Jungi TW, Brcic M, Eperon S, Albrecht S. Transforming growth factor-beta and interleukin-10, but not interleukin-4, down-regulate procoagulant activity and tissue factor expression in human monocyte-derived macrophages. Thromb Res 1994; 76: 463-474.
72. Ohsawa M, Koyama T, Yamamoto K, Hirosawa S, Kamei S, Kamiyama R. 1alpha, 25-dihydroxyvitamin D(3) and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Circulation 2000; 102: 2867-2872.
73. Soejima H, Ogawa H, Yasue H, et al. Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. J Am Coll Cardiol 1999; 34: 983-988.
74. Kim I, Oh JL, Ryu YS, et al. Angiopoietin-1 negatively regulates expression and activity of tissue factor in endothelial cells. FASEB J 2002; 16: 126-128.
75. Nakamura K, Kadotani Y, Ushigome H, et al. Antisense oligonucleotide for tissue factor inhibits hepatic ischemic reperfusion injury. Biochem Biophys Res Commun 2002; 297: 433-441.
76. Stephens AC, Rivers RP. Suppression of human monocyte tissue factor synthesis by antisense oligodeoxynucleotide. Thromb Res 1997; 85: 387-398.
77. Matsuyama M, Akioka K, Okamoto M, et al. Control of renal ischemic reperfusion injury by antisense oligodeoxynuceotide of tissue factor. Tansplant Proc 2003; 35: 103-104.
78. Verbon A, Meijers JC, Spek CA, et al. Effects of IC14, an anti-CD 14 antibody, on coagulation and fibrinolysis during low-grade endotoxemia in humans. J Infect Dis 2003; 187: 55-61.
79. Yang Z, Carter CD, Miller MS, Bochsler PN. CD14 and tissue factor expression by bacterial lipopolysaccharide-stimulated bovine alveolar macrophages in vitro. Infect Immun 1995; 63: 51-56.
80. Chu AJ, Moore J, Sime RM, Yu WS. Antagonism by ethanol of endotoxin-induced tissue factor activation in relation to the depressed endotoxin binding to monocyte-like TJ937 cells. Cell Biochem Funct 1997; 15: 271-281.
81. Chu AJ, Walton MA, Prasad JK, Seto A. Blockade of endotoxin recognition by polyunsaturated n-3 fatty acids is mediated by the altered receptor expression in monocytic THP-1 cells. J Surg Res 1999; 87: 217-224.
82. Park CT, Creasey AA, Wright SD. Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14. Blood 1997; 89: 4268-4274.
83. Derhaschnig U, Reiter R, Knobl P, Baumgartner M, Keen P, Jilma B. Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 2003; 102: 2093-2098.
84. Yamamoto K, Shimokawa T, Yi H, et al. Aging and obesity augment the stress-induced expression of tissue factor gene in the mouse. Blood 2002; 100: 4011-4018.
85. Bach RR, Moldow CF. Mechanism of tissue factor activation on HL-60 cells. Blood 1997; 89: 3270-3276.
86. Chu AJ, Wang ZG, Raphael UO. IV. Anticoagulant activity of compound 48/80: Inhibition of factor VII activation in Leukemia THP-1 monocytes. J Cardiovasc Pharmacol 2000; 36: 649-655.
87. Donate F, Kelly CR, Ruf W, Edgington TS. Dimerization of tissue factor supports solution-phase autoactivation of factor VII without influencing proteolytic activation of factor X. Biochemistry 2000; 39: 11467-11476.
88. Silverman MD, Waters CR, Hayman GT, Wigboldus J, Samet MM, Lelkes PI. Tissue factor activity is increased in human endothelial cells cultured under elevated static pressure. Am J Physiol 1999; 277: C233-C242.
89. Oguchi A, Morioka M, Obi N, Nishida J, Kinoshita T. Platelet activating factor causes a rapid increase in activity of prior expressed tissue factor on monocyte surface membrane. Int J Hematol 1999; 69: 119-125.
90. Giesen PL, Nemerson Y. Tissue factor on the loose. Semin Thromb Hemost 2000; 26: 379-384.
91. Engelmann B, Luther T, Muller I. Intravascular tissue factor pathway-a model for rapid initiation of coagulation within the blood vessel. Thromb Haemost 2003; 89: 3-8.
92. Giesen PL, Fyfe BS, Fallon JT, et al. Intimal tissue factor activity is released from the arterial wall after injury. Thromb Haemost 2000; 83: 622-628.
93. Muller I, Klocke A, Alex M, et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J 2003; 17: 476-478.
94. Lang D, Terstesse M, Dohle F, et al. Protein kinase C (PKC) dependent induction of tissue factor (TF) by mesangial cells in response to inflammatory mediators and release during apoptosis. Br J Pharmacol 2002; 137: 1116-1124.
95. Junker R, Heinrich J, Schulte H, van de Loo J, Assmann G. Cogaulation factor VII and the risk of coronary heart disease in healthy men. Artioscler Thromb Vasc Biol 1997; 17: 1539-1544.
96. Ridker PM, Bassuk SS, Toth PP. C-reactive protein and risk of cardiovascular disease: evidence and clinical application. Curr Atheroscler Rep 2003; 5: 341-349.
97. Chandler WL, Rodgers GM, Sprouse JT, Thompson AR. Elevated hemostatic factor levels as potential risk factors for thrombosis. Arch Pathol Lab Med 2002; 126: 1405-1414.
98. Ruf W, Edgington TS. An anti-tissue factor monoclonal antibody which inhibits TF:VIIa complex is a potent anticoagulant in plasma. Thromb Haemost 1991; 66: 529-533.
99. Chu AJ, Mathews ST. Anticoagulant potential of an antibody against factor VII. J Surg Res 2003; 114: 37-41.
100. Ettelaie C, Haris PI, James NJ, Wilbourn B, Adams JM, Bruckdorfer KR. Alterations in the structure of apolipoprotein B-100 determine the behaviour of LDL towards thromboplastin. Biochim Biophys Acta 1997; 1345: 237-247.
101. Conkling PR, Patton KL, Hannun YA, Greenberg CS, Weinberg JB. Sphingosine inhibits monocyte tissue factor-initiated coagulation by altering factor VII binding. J Biol Chem 1989; 264: 18440-18444.
102. Pitlick FA. Concanavalin A inhibits tissue factor coagulation activity. J Clin Invest 1975; 55: 175-179.
103. Chu AJ, Wang ZG, Fox MJ. III. Instantaneous inhibition by compound 48/80 of tissue factor-initiated coagulation is mediated by the downregulation of factor VII activation. Arch Biochem Biophys 2000; 377: 357-365.
104. Chu AJ, Wang ZG, Raicu M, Ramos N, Beydoun S. Protamine inhibits tissue factor-initiated extrinsic coagulation. Br J Haematol 2001; 115: 392-399.
105. Chu AJ, Wang ZG, Nwobi OI, Beydoun S. Blockade by ruthenium red of tissue factor-initiated coagulation. Br J Pharmacol 2001; 133: 659-664.
106. Chu AJ, Rauci M, Nwobi OI, Mathews ST, Beydoun S. Novel anticoagulant activity of polybrene: inhibition of monocytic tissue factor hypercoagulation following bacterial endotoxin induction. Blood Coagul Fibrinolysis 2002; 13: 123-128.
107. Chu AJ, Chen BM, Lin H, Beydoun S. Antimicrobial peptide Buforin I inhibits tissue factor-initiated coagulation. Arch Biochem Biophys 2001; 392; 3-7.
108. Chu AJ, Rauci M, Nwobi OI, Mathews ST, Beydoun S. Novel anticoagulant activity of polyamino acid offsets bacterial endotoxin-induced extrinsic hypercoagulation: downregulation of monocytic tissue factor-dependent FVII activation. J Cardiovasc Pharmacol 2003; 42: 477-483.
109. Chu AJ, Lin S-H, Piasentin E. Possible role of Marcks in the cellular modulation of monocytic tissue factor-initiated hypercoagulation. Br J Haematol 2002; 118: 569-576.
110. Rao LV, Nordfang O, Hoang AD, Pendurthi UR. Mechansim of antithrombin III inhibition of factor FVIIa/tissue factor activity on cell surface: comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood 1995; 85: 121-129.
111. Huang ZF, Wun TC, Broze GJ Jr. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 1993; 268: 26950-26955.
112. Francischetti IM, Valenzuela JG, Andersen JF, Mather TN, Ribeiro JM. Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex. Blood 2002; 99: 3602-3612.
113. Stanssens P, Bergum PW, Gansemans Y, et al. Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci USA 1996; 93: 2149-2154.
114. Moons AH, Peters RJ, Cate Ht H, et al. Recombinant Nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, agrogates endotoxin-induced coagulation in chimpanzees. Thromb Haemost 2002; 88: 627-631.
115. Sorensen BB, Rao LV. Interaction of activated factor VII and active site-inhibited activated factor VII with tissue factor. Blood Coagul Fibrinolysis 1998; (Suppl. 1): S67-S71.
116. Dennis MS, Eigenbrot C, Skelton NJ, et al. Peptide exosite inhibitors of factor VIIa as anticoagulants. Nature 2000; 404: 465-470.
117. Mahdi F, Rehemtulla A, Van Nostrand WE, Bajaj SP, Schmaier AH. Protease nexin-2/amyloid beta protein precursor regulates factor FVIIa and the factor VIIa-tissue factor complex. Thromb Res 2000 99: 267-276.
118. Lee GF, Kelley RF. A novel soluble tissue factor variant with an altered factor VIIa binding interface. J Biol Chem 1998; 273: 4149-4154.
119. Carson SD. Plasma high density lipoproteins inhibit the activation of coagulation factor X by factor VIIa and tissue factor. FEBS Letts 1981; 132: 37-40.
120. Gallus AS, Coghlan DW. Heparin pentasaccharide. Curr Opin Hematol 2002; 9: 422-429.
121. Hirsh J. Choice of low molecular weight heparins. J Thromb Haemost 2003; 1: 598-599.
122. Stassens P, Bergum PW, Gansemans Y, et al. Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci USA 1996; 93: 2149-2154.
123. Gaspar AR, Joubert AM, Crause JC, Neitz AW. Isolation and characterization of an anticoagulant from the salivary glands of the tick, Ornithodoros savignyi. Exp Appl Acarol 1999; 20: 583-598.
124. Hara T, Kunitada S, Iwamoto M. Dx-9065a, a synthetic and selective factor Xa inhibitor, species difference in its anticoagulant activity. Thromb Haemost 1993; 69: 890-899.
125. Hirsh J. Current anticoagulant therapy-unmet clinical needs. Thromb Res 2003; 109(Suppl. 1): S1-S8.
126. Nenci GG. Dermatan sulphate as an antithrombotic drug. Pathophysiol Haemost Thromb 2002; 32: 303-307.
127. Kaplan KL, Francis CW. Direct thrombin inhibitors. Semin Hematol 2002; 39: 187-196.
128. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269: 31869-31880.
129. Cera ED. Anticoagulant thrombins. Trends Cardiovasc Med 1998; 8: 340-360.
130. Church WR, Messier TL, Tucker MM, Mann KG. An inhibitory monoclonal antibody to factor X that blocks prothrombin activation but not prothrombinase enzyme assembly. Blood 1998; 72: 1911-1921.
131. Simmelink MJ, Horbach DA, Derksen RH, et al. Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces. Br J Haematol 2001; 113: 621-629.
132. Koppelt PW, Huijsmans CM, Nieuwenhuizen W. A monoclonal antibody, specific for human fibrinogen, fibrinopeptideA-containing fragmentsand not reacting with free fibrinopeptide A. Blood 1985; 66: 503-507.
133. Wallin R, Sane DC, Hutson SM. Vitamin K 2,3-epoxide reductase and the vitamin K-dependent gamma-carboxylation system. Thromb Res 2002; 108: 221-226.
134. Ichinose A, Kaetsu H. Molecular approach to structure-function relationship of human coagulation factor XIII. Method Enzymol 1993; 222: 36-51.
135. Standeven KF, Ariens RA, Whitaker P, Ashcroft AE, Weisel JW, Grant PJ. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes 2002; 51: 189-197.
136. Bromberg ME, Sundaram R, Homer RJ, Garen A, Konigsberg WH. Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule. Thromb Haemost 1999; 82: 88-92.
137. Sorensen BB, Rao LV, Tornehave D, Gammeltoft S, Petersen LC. Antiapoptotic effect of coagulation factor VIIa. Blood 2003; 102: 1708-1715.
138. Versteeg HH, Peppelenbosch MP, Spek CA. The pleiotropic effects of tissue factor: a possible role for factor VIIa-induced intracellular signaling? Thromb Haemost 2001; 86: 1353-1359.
139. Ollivier V, Bentolila S, Chabbat J, Hakim J, de Prost D. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood 1998; 91: 2698-2703.
140. Camerer E, Rottingen JA, Iversen JG, Prydz H. Coagulation factor VII and X induce Ca+2 oscillations in Madin-Darby canine kidney cells only when proteolytically active. J Biol Chem 1996; 271: 29034-29042.
141. Wang X, Gjernes E, Prydz H. Factor VIIa induces tissue factor-dependent up-regulation of interleukin-8 in human keratinocyte line. J Biol Chem 2002; 277: 23620-23626.
142. Siegbahn A, Johnell M, Rorsman C, Ezban M, Heldin CH, Ronnstrand L. Binding of factor VIIa to tissue factor on human fibroblasts leads to activation of phopholpase C and enhanced PDGF-BB-stimulated chemotaxis. Blood 2000; 96: 3452-3458.
143. Riewald M, Kravchenko VV, Petrovan RJ, et al. Gene induction by coagulation factor Xa is mediated by activation of protease-activated receptor 1. Blood 2001; 97: 3109-3116.
144. Jones A, Geczy CL. Thrombin and factor Xa enhance the production of interleukine-1. Immunology 1990; 71: 236-241.
145. Senden NH, Jeunhomme TM, Heemskerk JW, et al. Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells. J Immunol 1998; 161: 4318-4324.
146. Ollivier V, Chabbat J, Herbert JM, Hakim J, de Prost D. Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa. Arterioscler Thromb Vasc Biol 2000; 20: 1374-1381.
147. Breschneider E, Braun M, Fischer A, Wittpoth M, Glusa E, Schror K. Factor Xa acts as a PDGF-independent mitogen in human vascular smooth muscle cells. Thromb Haemost 2000; 84: 499-505.
148. Monno R, Grandaliano G, Faccio R, et al. Activated coagulation factor X: a novel mitogenic stimulatus for human mesangial cells. J Am Soc Nephrol 2001; 12: 891-899.
149. Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci USA 1999; 96: 11023-11027.
150. Naldini A, Sower L, Bocci V, Meyers B, Carney DH. Thrombin receptor expression and responsiveness of human monocytic cells to thrombin is link to interferon-induced cellular differentiation. J Cell Physiol 1998; 177: 76-84.
151. Hoffmann M, Cooper ST. Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1 beta by two distinct mechanisms. Blood Cells Mol Dis 1995; 21: 156-167.
152. Wakita H, Furukawa F, Takigawa M. Thrombin and trypsin induce granulocyte-macrophage colony-stimulating factor and interleukin-6 gene expression in cultured normal human keratinocytes. Proc Assoc Am Physicians 1997; 109: 190-207.
153. Suk K, Cha S. Thrombin-induced interleukin 8 production and its regulation by interferon-gamma and prostaglandin E2 in human monocytic U937 cells. Immunol Lett 1999; 67: 223-227.
154. Marin V, Farnarier C, Gres S, et al. The p38 mitogen-activated protein kinase pathway plays a critical role in thrombin-induced endothelial chemokine production and leukocytye recruitment. Blood 2001; 98: 667-673.
155. Kaplanski G, Fabrigoule M, Boulay V, et al. Thrombin induces endothelial type II activation in vitro: IL-1 and TNF-alpha-independent IL-8 secretion and E-selectin expression. J Immunol 1997; 158: 5435-5441.
156. Cucina A, Borreli V, Di Carlo A, et al. Thrombin induces production of growth factors from aortic smooth muscle cells. J Surg Res 1999; 82: 61-66.
157. Takata M, Urakaze M, Temaru R, et al. Pravastatin suppresses the inter91eukin-8 production induced by thrombin in human arotic endothelial cells cultured with high glucose by inhibiting the p44/42 mitogen activated protein kinase. Br J Pharmacol 2001; 134: 753-762.
158. Huang YQ, Li JJ, Hu L, Lee M, Karpatkin S. Thrombin induces increased expression and secreation of VEGF from human FS4 fibroblasts, DU145 prostate cells and CHRF megakaryocytes. Thromb Haemost 2001; 86: 1094-1098.
159. Kaplanski G, Marin V, Fabrigoule M, et al. Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106). Blood 1998; 92: 1259-1267.
160. Minami T, Aird WC. Thrombin stimulation of the vascular cell adhesion molecule-1 promoter in endothelial cells is mediated by tandem nuclear factor-kappa B and GATA motifs. J Biol Chem 276: 47632-47641.
161. Lampugnani MG, Colotta F, Polentarutti N, Pedenovi M, Mantovani A, Dejana E. Thrombin induces c-fos expression in cultured human endothelial cells by a Ca+2-dependent mechansim. Blood 1990; 76: 1173-1180.
162. Lee ME, Kweon SM, Nham SU. Fibrin stimulates microfilament reorganization and IL-1 beta production in human monocytic THP-1 cells. Mol Cell 2001; 11: 13-20.
163. Liu X, Piela-Smith TH. Fibrin(ogen)-induced expression of ICAM-1 and chemokines in human synovial fibroblasts. J Immunol 2000; 165: 5255-5261.
164. Robson SC, Shephard EG, Kirsch RE. Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol 1994; 86: 322-326.
165. Hamaguchi M, Morishita Y, Takahashi I, Ogura M, Takamatsu J, Saito H. FDP D-dimer induces the secretion of interleukin-1, urokinase-type-plasminogen activator, and plasminiogen activator inhibitor-2 in a human promonocytic leukiemia cell line. Blood 1991; 77: 94-100.
166. Csala M, Lerant I, Banhegyi G, et al. Prostaglandin-independent stimulation of interleukin-6 production by fibrinogen degradation product D in perfused murine liver. Scand J Immunol 48: 269-271.
167. Lee ME, Rhee KJ, Nham SU. Fragment E derived from both fibrin and fibrinogen stimulates interleukin-6 production in rat peritoneal macrophages. Mol Cell 1999; 9: 7-13.
168. Bootle-Wilbraham CA, Tazzyman S, Thompson WD, Stirk CM, Lewis CE. Fibrin fragment E stimulates the proliferation, migration and differentiation of human microvascular endothelial cells in vitro. Angiogenesis 2001; 4: 269-275.
169. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001; 103: 1718-1720.
170. Kluft C, Gevers Leuven JA, Helmerhorst FM, Krans HMJ. Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormaone replacement treatment. Vasc Pharmacol 2002; 39: 149-154.
171. Saibeni S, Cattaneo M, Vecchi M, et al. Low vitamin B6 plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants. Am J Gastroenterol 2003; 98: 112-117.
172. Barnes PI, Karin M. Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1071.
173. Taylor FB Jr, Chang A, Ruf W, et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33: 127-134.
174. Cunningham MA, Romas P, Hutchinson P, Holdsworth SR, Tipping PG. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages. Blood 1999; 94: 3413-3420.
175. De Jonge E, Friederich PW, Vlasuk GP, et al. Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects. Clin Diagn Lab Immunol 2003; 10: 495-497.
176. Kruithof EK, Agay D, Mestries JC, Gascon MP, Ythier A. The effect of factor Xa/phospholipid infusion on the acute phase response in baboons. Thromb Haemost 1997; 77: 308-311.
177. Szaba FM, Smiley ST. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood 2002; 99: 1053-1059.
178. Schmid E, Muller TH, Budzinski RM, Binder K, Pfizenmaier K. Signaling by E-selectin and ICAM-1 induces endothelial tissue factor production via autocrine secretion of platelet-activating factor and tumor necrosis factor alpha. J Interferon Cytokine Res 1995; 15: 819-825.
179. Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 2000; 20: 2322-2328.
180. Kruithof EK, Mestries JC, Gascon MP, Ythier A. The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation-effect of interleukin 6. Thromb Haemost 1997; 77: 905-910.
181. Falati S, Liu Q, Gross P, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin J Exp Med 2003; 197: 1585-1598.
182. Armstead VE, Minchenko AG, Scalla R, Lefer AM. Pulmonary tissue factor mRNA expression during murine traumatic shock: effect of P-selectin blockade. Shock 2001; 15: 323-326.
183. Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner DD. Procoagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci USA 2000; 97: 13835-13840.
184. Sullivan VV, Hawley AE, Farris DM, et al. Decrease in fibrin content of venous thrombi in selectin-deficient mice. J Surg Res 2003; 109: 1-7.
185. Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 1997; 96: 396-399.
186. Camerer E, Rottinhen JA, Gjernes E, et al. Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene. J Biol Chem 1999; 274: 32225-32233.
187. Akahane K, Okamoto K, Kikuchi M, et al. Inhibition of factor Xa suppresses the expression of tissue factor in human monocytes and lipopolysaccharide-induced endotoxemia in rats. Surgery 2001; 130: 809-818.
188. Chen D, Riesbeck K, McVey JH, et al. Human thrombin and FXa mediate porcine endothelial cell activation; modulation by expression of TFPI-CD4 and hirudin-CD4 fusion proteins. Xenotransplantation 2001; 8: 258-265.
189. Miller DL, Welty-Wolf K, Carraway MS, et al. Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol 2002; 26: 650-658.
190. Pernerstorfer T, Hollenstein U, Hansen J, et al. Heparin blunts endotoxin-induced coagulation activation. Circulation 1999; 100: 2485-2490.
191. Gerotziafas GT, Bara L, Bloch MF, Makris PE, Samama MM. Treatment with LMWHs inhibits factor VIIa generation during in vitro coagulation of whole blood. Thromb Res 81: 491-496.
192. Gertz SD, Fallon JT, Gallo R, et al. Hirudin reduces tissue factor expression in neointima after ballon injury in rabbit femoral and porcine coronary arteries. Cirulation 1998; 98: 580-587.
193. Chen X, Ren S, Ma MG, et al. Hirulog-like peptide reduces restenosis and expression of tissue factor and transforming growth factor-beta in carotid artery of atherosclerotic rabbits. Atherosclerosis 2003; 169: 31-40.
194. Pouplard C, Iochmann S, Renard B, et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 2001; 97: 3300-3302.
195. Slungaard A, Fernandez JA, Griffin JH, et al. Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood 2003; 102: 146-151.
196. Caplice NM, Mueske CS, Kleppe LS, Simari RD. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation 98: 1051-1057.
197. Murphy JF, McGregor JL. A peptide (P2) derived from the variable heavy chain of an anti-P-selectin monoclonal antibody (LYP20) inhibits leucocyte adhesion to thrombin-activated platelets and endothelial cells. Br J Haematol 2003; 120: 605-610.
198. Leytin V, Shakoor S, Mody M, Allen D, Garvey B, Freedman J. Sepsis- and endotoxemia-generated cytokines do not trigger activation of human platelets. Crit Care Med 2002; 30: 2771-2773.
199. Henke PK, Wakefield TW, Kadell AM, et al. Interleukin-8 administration enhances venous thrombosis resolution in a rat model. J Surg Res 2001; 99: 84-91.
200. Palabrica T, Lobb R, Furie BC, et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992; 359: 848-851.
201. Thanaporn P, Myers DD, Wrobleski SK, et al. P-selectin inhibition decreases post-thrombotic vein wall fibrosis in a rat model. Surgery 2003; 134: 365-371.
202. Toombs CF, DeGraaf GL, Martin JP, Geng JG, Anderson DC, Shebuski RJ. Pretreatment with a blocking monoclonal antibody to P-selectin accelerates pharmacological thrombolysis in a primate model of arterial thrombosis. J Pharmacol Exp Ther 1995; 275: 941-949.
203. Wakefield TW, Strieter RM, Wilke CA, et al. Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules. Arterioscler Thromb Vasc Biol 1995; 15: 258-268.
204. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136: 161-172.
205. McKenzie ME, Malinin AI, Bell CR, et al. Aspirin inhibits surface glycoprotein IIb/IIIa, P-selectin, CD63, and CD107a receptor expression on human platelets. Blood Coagul Fibrinolysis 2003; 14: 249-253.
206. Pitt B, Pepine C, Willerson JT. Cyclooxygenase-2 inhibition and cardiovascular events. Circulation 2002; 106: 167-169.
207. de Gaetano G, Donati MB, Cerletti C. Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors. Trends Pharmacol Sci 2003; 24: 245-252.
208. Smith A, Quarmby JW, Collins M, Lockhart SM, Burnand KG. Changes in the levels of soluble adhesion molecules and coagulation factors in patients with deep vein thrombosis. Thromb Haemost 1999; 82: 1593-1599.
209. Ahmad S, Jeske WP, Ma Q, Walenga JM, Fareed J. Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist. Thromb Res 2001; 102: 143-151.
210. Carr ME Jr, Martin EJ, Kuhn JG, Seremetis SV. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion. Thromb Haemost 2003; 89: 803-811.
211. Bouchard BA, Butenas S, Mann KG, Tracy PB. Interaction between platelets and the coagulation system. In Platelets, Michelson A (ed.). Academic Press: San Diego, 2002; 229-253.
212. Ten Berg JM, Gerritsen WB, Haas FJ, Kelder JC, Verheugt FW, Thijs Plokker HW. Pretreatment with oral anticoagulants decreases platelet activation in patients before and after percutaneous coronary intervention. Thromb Haemost 2002; 88: 924-930.
213. Kaiser B, Jeske W, Walenga JM, Fareed J. Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood. Blood Coagul Fibrinolysis 1999; 10: 495-501.
214. Annex BH, Davies MG, Fulton GJ, et al. Local delivery of a tissue factor antibody reduces early leukocyte infiltration but fails to limit intimai hyperplasia in experimental vein grafts. J Surg Res 1998; 80: 164-170.
215. Iba T, Kidokoro A, Fukunaga M, et al. Factor Xa-inhibitor (DX-9065a) modulates the leukocyte-endothelial cell interaction in endotoxemic rat. Shock 2002; 17: 159-162.
216. Libby P. Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis and stabilization. Am J Cardiol 2000; 86(Suppl.): 3J-9J.
217. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
218. Gotto AM Jr. Treating hypercholesterolemia: looking forward. Clin Cardiol 2003; 26(Suppl. 1): 121-128.
219. Powell RC. An update on the hyperlipidemias and atherosclerosis. Indiana Med 1984; 77: 441-445.
220. Holvoet P, Collen D. Thrombosis and atherosclerosis. Curr Opin Lipidol 1997; 8: 320-328.
221. Kullo IJ, Gau GT, Tajik AJ. Novel risk factors for atherosclerosis. Mayo Clin Proc 2000; 75: 369-380.
222. Tufano A, Coppola A, Loffredo F, Garofano T, Celentano A, DiMinno G. Hypercoagulability and atherothrombosis: clinical suggestions and perspectives. Haematologica 2001; 86: 8-11.
223. Allen S, Khan S, Tam S, Koschinsky M, Taylor P, Yacoub M. Expression of adhesion molecules by 1p(a): a potential novel mechanism for its atherogenicity. FASEB J 1998; 12: 1765-1776.
224. Drake TA, Hannani K, Fei HH, Lavi S, Berliner JA. Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells. Am J Pathol 1991; 138: 601-607.
225. Kita T, Kume N, Minami M, et al. Role of oxidized LDL in atherosclerosis. Ann N Y Acad Sci 2001; 947: 199-205.
226. Liao L, Starzyk RM, Granger DN. Molecular determinants of oxidized low-density lipoprotein-induced leukocyte adhesion and microvascular dysfunction. Arterioscler Thromb Vasc Biol 1997; 17: 437-444.
227. Schonbeck U, Gerdes N, Varo N, et al. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation 2002; 106: 2888-2893.
228. Wang G, Woo CW, Sung FL, Siow YL, O K. Increased monocyte adhesion to aortic endothelium in rats with hyperhomocysteinemia: role of chemokine and adhesion molecules. Arterioscler Thromb Vasc Biol 2002; 22: 1777-1783.
229. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003; 169: 203-214.
230. Vasankari T, Ahotupa M, Toikka J, et al. Oxidized LDL and thickness of carotid intima-media are associated with coronary atherosclerosis in middle-aged men: lower levels of oxidized LDL with statin therapy. Atherosclerosis 2001; 155: 403-412.
231. van Wissen S, Smilde TJ, Trip MD, de Boo T, Kastelein JJ, Stalenhoef AF. Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia. Heart 2003; 89: 893-896.
232. Marz W, Koenig W. HMG-CoA reductase inhibition: antiinflammatory effects beyond lipid lowering? J Cardiovasc Risk 2003; 10: 169-179.
233. Nawawi H, Osman NS, Yusoff K, Khalid BA. Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia. Horm Metab Res 2003; 35: 479-485.
234. Pruefer D, Makowski J, Schnell M, et al. Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation 2002; 106: 2104-2110.
235. Souter PJ, Thomas S, Hubbard AR, Poole S, Romisch J, Gray E. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med 2001; 29: 134-139.
236. Levi M, van der Poll T, ten Cate H, van Deventer SJH. The cytokine-mediated imblanced between coagulation and anticoagulation mechanism in sepsis and endotoxemia. Eur J Clin Invest 1997; 27: 3-9.
237. Totzke G, Schobersberger W, Schloesser M, Czechowski M, Hoffmann GJ. Effects of antithrombin III on tumor necrosis factor-alpha and interleukin-1 beta synthesis in vascular smooth cells. J Interferon Cytokine Res 2001; 21: 1063-1069.
238. Zuo XJ, Nicolaidou E, Okada Y, Toyoda M, Jordan SC. Antithrombin III inhibts lymphocyte proliferation, immunoglobulin production and mRNA expression of lymphocyte growth factors (IL-2, gamma-IFN and IL-4) in vitro. Transpl Immunol 2001; 9: 1-6.
239. Oelschlager C, Romisch J, Staubitz A, et al. Antithrombin III inhibits nuclear factor kappa B activation in human monocytes and vascular endothelial cells. Blood 2002; 99: 4015-4020.
240. Isobe H, Okajima K, Uchiba M, Harada N, Okabe H. Antithrombin prevents endotoxin-induced hyptension by inhibiting the induction of nitric oxide synthesis in rats. Blood 2002; 99: 1638-1645.
241. Yamashiro K, Kiryu J, Tsujikawa A, et al. Inhibitory effects of antithrombin III against leukocyte rolling and infiltration during endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci 2001; 42: 1553-1560.
242. Kaneider NC, Rabensteiner A, Reinisch CM, Dunzendorfer S, Wiedermann CJ. Inhibition of human neutrophil chemotaxis toward interleukine 8 with six cinical antithrombin concentrates in vitro. Intensive Care Med 2002; 28: 1447-1452.
243. Opal SM. Therapeutic rationale for antithrombin III. Crit Care Med 2000; 28: S34-S37.
244. Minnema MC, Chang ACK, Jansen PM, et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with E. coli. Blood 2000; 95: 1117-1123.
245. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patients: high-dose antithrombin III in severe sepsis: a randomized controlled triahttp://travel.state.gov/dv2005.html 1. JAMA 2001; 286: 1869-1878.
246. Yuksel M, Uchiba M, Okjima K, Okabe H. Activated protein C inhibits LPS-induced production of TNF-α by monocytes through inhibtion of activation of NFκB and MAPK pathways. Thromb Haemost 2001; 85: S508-S516.
247. Hancock WW, Grey ST, Hau L, et al. Binding of activated protein C to a specific receptor on human monocuclear phagocytes inhibits intracellular calium signaling and monocyte dependent proliferative responses. Transplanation 1995; 60: 1525-1532.
248. White B, Schmidt M, Murrph C, et al. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor κB (NF-κB) and tumor necrosis factor a (TNF-κ) production in the THP-1 moncytic cell line. Br J Haematol 2000; 110: 130-134.
249. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276: 11199-11203.
250. Barnard GR, Ely EW, Wright TJ, et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001; 29: 2051-2059.
251. Barnard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
252. Nimah M, Brilli RJ. Coagulation dysfunction in sepsis and multiple organ system failure. Crit Care Clin 2003; 19: 441-458.
253. Joyce DE, Grinnell BW. Recombinant human activated protein C animates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappa B. Crit Care Med 2002; 30: S288-S293.
254. Hooper WC, Phillips DJ, Renshaw MA, Evatt BL, Benson JM. The up-regulation of IL-6 and IL-8 in human endothelial cells by activated protein C. J Immunol 1998; 161: 2567-2573.
255. Hooper WC, Phillips DJ, Renshaw MA. Activated protein C induction of MCP-1 in human endothelial cells: a possible role for edothelial cell nitric oxide synthase. Thromb Res 2001; 103: 209-219.
256. Johnson K, Aarden L, Choi Y, De Groot E, Creasey A. The proinflammatory cytokine response to coagulation and endotoxin in whole blood. Blood 1996; 87: 5051-5060.
257. Creasey AA, Chang AC, Fiegen L, Wun TC, Taylor FB, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from E. coli septic shock. J Clin Invest 1993; 91: 2850-2860.
258. de Jonge E, Dekkers PE, Creasey AA, et al. Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia. J Infect Dis 2001; 183: 1815-1818.
259. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290: 238-247.
260. Freeman BD, Zehnbauer BA, Buchman TG. A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis. Shock 2003; 20: 5-9.
261. Carraway MS, Welty-Wolf KE, Miller DL, et al. Blockade of tissue factor: treatment for organ injury in established sepsis. Am J Respir Crit Care Med 2003; 167: 1200-1209.
262. Taylor FB, Chang AC, Peer G, Li A, Ezban M, Hedner U. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli. Blood 1998; 91: 1609-1615.
263. Jilma B, Marsik C, Mayr F, et al. Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans. Clin Pharmacol Ther 2002; 72: 403-410.
264. Auge C, Dagron F, Lemoine R, Le Narvor C, Lubineau A. Oligosaccharide sulfate inhibitors of selectin-sugar interactions in inflammatory processes. Ann Pharm Fr 1999; 57: 216-222.
265. Call DR, Remick DG. Low molecular weight heparin is associated with greater cytokine production in a stimulated whole blood model. Shock 1998; 10: 192-197.
266. Hollenstein UM, Pernerstorfer T, Homoncik M, et al. Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis 2002; 186: 1270-1276.
267. Tyrrell DJ, Home AP, Holme KR, Preuss JMH, Page CP. Heparin in inflammation: potential therapectic applications beyond anticoagulation. In Advances in Pharmacology, vol 46. Academic Press: San Diego, 1999; 151-208.
268. Aldea GS, Scltow LO, Chandler WL, et al. Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuit. J Thorac Cardiovasc Surg 2002; 123: 742-755.
269. Koster A, Fischer T, Praus M, et al. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiolgy 2002; 97: 837-841.
270. Wang L, Brown JR, Varki A, Esko JD. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 2002; 110: 127-136.
271. Wang JG, Geng JG. Affinity and kinetics of P-selectin binding to heparin. Thromb Haemost 2003; 90: 309-316.
272. Luo J, Kato M, Wang H, Bernfield M, Bischoff J. Heparan sulfate and chondroitin sulfate proteoglycans inhibit E-selectin binding to endothelial cells. J Cell Biochem 2001; 80: 522-531.
273. Matsumiya A, Yamaguchi M, Nakano H, Takeda M, Kumada K. Dextran sulfate inhibits E-selectin-mediated neutrophil adhesion to endotoxin-activated vascular endothelial cells. Life Sci 1999; 64: PL9-PL17.
274. Granell S, Gironella M, Bulbena O, et al. Heparin mobilizes xanthine oxidase and induces lung inflammation in acute pancreatitis. Crit Carde Med 2003; 31: 525-530.
275. Butler J, Murithi EW, Pathi VL, MacArthur KJ, Berg GA. Duroflo II heparin bonding does not attenuate cytokine release or improve pulmonary function. Ann Thorac Surg 2002; 74: 139-142.
276. Amin HM, Ahmad S, Walenga JM, Hoppensteadt DA, Leitz H, Fareed J. Soluble P-selectin in human plasma: effect of anticoagulant matrix and its levels in patients with cardiovascular disorders. Clin Appl Thromb Hemost 2000; 6: 71-76.
277. Kanemitsu S, Nishikawa M, Onoda K, et al. Pharmacologic platelet anesthesia by glycoprotein IIb/IIIa complex antagonist and argatroban during in vitro extracorporeal circulation. J Thorac Cardiovasc Surg 2003; 126: 428-435.
278. Caunt M, Huang YQ, Brooks PC, Karpatkin S. Thrombin induces neoangiogenesis in the chick chorioallantoic membrane. J Thromb Haemost 2003; 1: 2097-2102.
279. Kranzhofer R, Maraganore JM, Baciu R, Libby P. Systemic thrombin inhibition by Hirulog does not alter medial smooth muscle cell proliferation and inflammatory activation after vascular injury in the rabbit. Cardiovasc Drugs Ther 1999; 13: 429-434.
280. Suleymanov OD, Szalony JA, Salyers AK, et al. Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model. J Pharmacol Exp Ther 2003; 306: 1115-1121.
281. Soderstrom T, Hedner U, Arnljots B. Active site-inactivated factor VIIa prevents thrombosis without increased surgical bleeding: topical and intravenous administration in a rat model of deep arterial injury. J Vasc Surg 2001; 33: 1072-1079.
282. Jakobsen P, Pedersen BR, Persson E. Inhibitors of the tissue factor/factor VIIa-induced coagulation: synthesis and in vitro evaluation of novel specific 2-aryl sbstituted 4H-3,1-benzoxazin-4-ones. Bioorg Med Chem 2000; 8: 2095-2103.